| A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects (NCT03804645) | AstraZeneca | 2019-02-05 |
| BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS) (NCT03925415) | AstraZeneca | 2019-01-24 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration (NCT03801967) | AstraZeneca | 2019-01-24 |
| A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately. (NCT03772223) | AstraZeneca | 2019-01-21 |
| Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma (NCT03788746) | AstraZeneca | 2019-01-17 |
| A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects (NCT03836599) | AstraZeneca | 2019-01-16 |
| Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (NCT03706079) | AstraZeneca | 2019-01-07 |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (NCT03737643) | AstraZeneca | 2019-01-04 |
| A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects (NCT03622112) | AstraZeneca | 2019-01-02 |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (NCT03819465) | AstraZeneca | 2018-12-27 |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (NCT03742102) | AstraZeneca | 2018-12-21 |
| Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (NCT03775486) | AstraZeneca | 2018-12-21 |
| First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy (NCT03798535) | AstraZeneca | 2018-12-19 |
| An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03759288) | AstraZeneca | 2018-12-07 |
| A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (NCT03800134) | AstraZeneca | 2018-12-06 |
| A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449 (NCT03766399) | AstraZeneca | 2018-11-30 |
| A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (NCT03778957) | AstraZeneca | 2018-11-30 |
| Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients (NCT03721289) | AstraZeneca | 2018-11-29 |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (NCT03706690) | AstraZeneca | 2018-11-27 |
| A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (NCT03725475) | AstraZeneca | 2018-11-26 |
| Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy (NCT03755934) | AstraZeneca | 2018-11-19 |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NCT03732677) | AstraZeneca | 2018-11-16 |
| Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. (NCT03833141) | AstraZeneca | 2018-11-12 |
| A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients (NCT03736473) | AstraZeneca | 2018-11-07 |
| Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) (NCT03688074) | AstraZeneca | 2018-11-02 |
| Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium (NCT03682497) | AstraZeneca | 2018-11-01 |
| AZD4635 Relative Bioavailability Study (NCT03710434) | AstraZeneca | 2018-11-01 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (NCT03732820) | AstraZeneca | 2018-10-31 |
| ALEXANDRIA Study Egypt (NCT03583463) | AstraZeneca | 2018-10-29 |
| Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (NCT03463525) | AstraZeneca | 2018-10-24 |
| Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (NCT03616587) | AstraZeneca | 2018-10-11 |
| A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. (NCT03645434) | AstraZeneca | 2018-10-10 |
| Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong (NCT03519958) | AstraZeneca | 2018-09-30 |
| Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NCT03682068) | AstraZeneca | 2018-09-27 |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (NCT03703297) | AstraZeneca | 2018-09-27 |
| Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease (NCT03615924) | AstraZeneca | 2018-09-26 |
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium (NCT03761901) | AstraZeneca | 2018-09-21 |
| The Study for Evaluating Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients With COPD. (NCT03642613) | AstraZeneca | 2018-09-14 |
| A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants (NCT03649165) | AstraZeneca | 2018-09-05 |
| A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate (NCT03740373) | AstraZeneca | 2018-09-04 |
| Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (NCT03619213) | AstraZeneca | 2018-08-27 |
| Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (NCT03562819) | AstraZeneca | 2018-08-16 |
| Lynparza Breast Cancer Clinical Experience Investigation (NCT03590938) | AstraZeneca | 2018-08-14 |
| Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes (NCT03645421) | AstraZeneca | 2018-08-10 |
| Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03616821) | AstraZeneca | 2018-08-07 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels. (NCT03593785) | AstraZeneca | 2018-08-03 |
| Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma (NCT03557307) | AstraZeneca | 2018-08-01 |
| A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants. (NCT03436316) | AstraZeneca | 2018-07-26 |
| A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer (NCT03553563) | AstraZeneca | 2018-07-24 |
| A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (NCT03521154) | AstraZeneca | 2018-07-19 |
| S-CEI of Nexium in Paediatric Patients (NCT03562026) | AstraZeneca | 2018-06-28 |
| Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (NCT03532009) | AstraZeneca | 2018-06-26 |
| A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society (NCT03577795) | AstraZeneca | 2018-06-19 |
| Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD Patients (NCT03359122) | AstraZeneca | 2018-06-07 |
| A Ph 1 Study of Epanova® in Healthy Chineses (NCT03574142) | AstraZeneca | 2018-06-04 |
| FASENRA SCEI for Long-term Use (NCT03588546) | AstraZeneca | 2018-05-31 |
| A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (NCT03239340) | AstraZeneca | 2018-05-30 |
| Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (NCT03534453) | AstraZeneca | 2018-05-29 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) (NCT03505307) | AstraZeneca | 2018-05-21 |
| A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (NCT03553108) | AstraZeneca | 2018-05-16 |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (NCT03528694) | AstraZeneca | 2018-05-14 |
| Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (NCT03509012) | AstraZeneca | 2018-05-02 |
| Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy (NCT03629782) | AstraZeneca | 2018-04-26 |
| Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR) (NCT03694470) | AstraZeneca | 2018-04-15 |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer (NCT03423628) | AstraZeneca | 2018-04-02 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer (NCT03519971) | AstraZeneca | 2018-03-29 |
| PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) (NCT03492931) | AstraZeneca | 2018-03-28 |
| A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects (NCT03450759) | AstraZeneca | 2018-03-28 |
| ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow (NCT03654157) | AstraZeneca | 2018-03-25 |
| Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (NCT03471572) | AstraZeneca | 2018-03-22 |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. (NCT03330847) | AstraZeneca | 2018-03-07 |
| Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (NCT03406078) | AstraZeneca | 2018-03-05 |
| ADHERE-S (NIS Brilique) (NCT03444012) | AstraZeneca | 2018-03-05 |
| Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. (NCT03338855) | AstraZeneca | 2018-03-05 |
| A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients (NCT03387683) | AstraZeneca | 2018-02-28 |
| Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects (NCT03435276) | AstraZeneca | 2018-02-27 |
| Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) (NCT03373045) | AstraZeneca | 2018-02-27 |
| iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases (NCT03549754) | AstraZeneca | 2018-02-17 |
| Prospective Tissue Collection Research Protocol (NCT03517917) | AstraZeneca | 2018-02-08 |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (NCT03421353) | AstraZeneca | 2018-02-07 |
| AZD8601 Study in CABG Patients (NCT03370887) | AstraZeneca | 2018-02-05 |
| A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers (NCT03420092) | AstraZeneca | 2018-02-05 |
| China Ovarian Cancer BRCA Testing Study (NCT03203993) | AstraZeneca | 2018-01-31 |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies (NCT03394144) | AstraZeneca | 2018-01-30 |
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (NCT03402841) | AstraZeneca | 2018-01-30 |
| THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (NCT03354429) | AstraZeneca | 2018-01-22 |
| Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis (NCT03368235) | AstraZeneca | 2018-01-18 |
| To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. (NCT03286842) | AstraZeneca | 2018-01-17 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men (NCT03400488) | AstraZeneca | 2018-01-16 |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (NCT03401229) | AstraZeneca | 2018-01-15 |
| Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study (NCT03387722) | AstraZeneca | 2017-12-31 |
| Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma (NCT03371459) | AstraZeneca | 2017-12-29 |
| Brilinta Clinical Experience Investigation (NCT03212287) | AstraZeneca | 2017-12-21 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (NCT03334617) | AstraZeneca | 2017-12-18 |
| Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma (NCT03364608) | AstraZeneca | 2017-12-15 |
| A Phase IV Study in Drug-Naive Patients With T2DM in China (NCT03344341) | AstraZeneca | 2017-12-15 |
| A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. (NCT03303521) | AstraZeneca | 2017-12-14 |
| Indian Phenotype Registry (NCT03363594) | AstraZeneca | 2017-12-11 |
| To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease (NCT03181880) | AstraZeneca | 2017-12-04 |